Migraine with aura after clopidogrel withdrawal: evidence of inflammation as a migraine trigger? – Case report
DOI:
https://doi.org/10.48208/HeadacheMed.2022.36Keywords:
Patent foramen ovale, Clopidogrel, Migraine with aura, Ischemic Stroke, InflamationAbstract
This article presents the case of a PFO (patent foramen ovale) closure patient with double antiplatelet therapy in whom aspirin was discontinued before clopidogrel and that, at clopidogrel withdrawal, presented “de novo” migraine with visual aura attacks. Migraines with aura associated with atrial right-to-left shunts (PFO and other atrial septal defects) are attributed to the arrival of vasoactive substances in the brain, since not cleared by the lungs. In this case, discontinuation of clopidogrel one year after PFO closure induced “de novo” migraine with aura.
Conclusion
Rather than confirming the prophylactic effects of clopidogrel for migraine with aura, its triggering at clopidogrel withdrawal is more likely related to a proinflammatory effect of discontinuing clopidogrel. This proinflammatory effect has been described in cardiological research, and reinforces that patients receiving dual antiplatelet therapy (clopidogrel and aspirin) should always have clopidogrel discontinued before aspirin in order to avoid proinflammatory or pro-thrombotic events.
Downloads
References
Chow, G., & Ziegelstein, R. C.. Clopidogrel. American Journal of Cardiovascular Drugs, 7(3), 2007:169–171. DOI: https://doi.org/10.2165/00129784-200707030-00003
Hackam DG, Spence JD. Antiplatelet Therapy in ischemic stroke and transient ischemic attack. stroke. 2019;50(3):773-778. DOI: https://doi.org/10.1161/STROKEAHA.118.023954
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes. 2006; 55: 780-784. DOI: https://doi.org/10.2337/diabetes.55.03.06.db05-1394
Savonitto S, D’Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ’bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel 2010; 104: 285-291. DOI: https://doi.org/10.1093/bja/aep373
Sathasivam S, Sathasivam S. Patent foramen ovale and migraine: What is the relationship between the two? J Cardiol 2013; 61: 256–259. DOI: https://doi.org/10.1016/j.jjcc.2012.12.005
Zeller JA, Frahm K, Baron R, et al. Platelet-leukocyte interaction and platelet activation in migraine: A link to ischemic stroke? J Neurol Neurosurg Psychiatry 2004; 75: 984–987. DOI: https://doi.org/10.1136/jnnp.2003.019638
Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740–1746. DOI: https://doi.org/10.1056/NEJMoa011503
Chambers JB, Seed PT, Ridsdale L. Clopidogrel as prophylactic treatment for migraine: a pilot randomised, controlled study. Cephalalgia 2014; 34: 63-68. DOI: https://doi.org/10.1177/0333102414531156
Spencer BT, Qureshi Y, Sommer RJ. A retrospective review of clopidogrel as primary therapy for migraineurs with right to left shunt lesions. Cephalalgia 2014; 34: 933-937. DOI: https://doi.org/10.1177/0333102414523845
Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006; 27: 647–654. DOI: https://doi.org/10.1093/eurheartj/ehi684
Wilmshurst PT, Nightingale S, Walsh KP et al. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart 2005; 91: 1173–1175. DOI: https://doi.org/10.1136/hrt.2004.047746
Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. J Am Coll Cardiol 2006; 47:446–448.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Caroline Mensor Folchini, Paulo Sergio Faro Santos, Jessica Giraldes, Amanda Batista Machado, Pedro André Kowacs
This work is licensed under a Creative Commons Attribution 4.0 International License.
